Protocols›Healing & recovery›Tissue Repair — Clinic
← Protocols
US-clinic · off-labelAthlete / performance · uptakeNo approved clinical use

Tissue Repair — Clinic

Stack: BPC-157 + TB-500 + MGF + GHK-Cu · higher-intensity repair
"The higher-intensity, clinic-supervised version of the repair stack. More compounds and higher intent mean supervision matters more, not less — and the evidence is still preclinical."
GoalHigher-intensity repair
Compounds4 · BPC-157 + TB-500 + MGF + GHK-Cu
Humans exposed (est.)Moderate — undocumented
StatusMHRA (UK): not licensed medicines — research material · FDA (US): BPC-157 / TB-500 status evolving · physician-supervised use recommended
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
US-clinic
Where / who
Community / athlete and clinic use as tagged above.
Use status
Used in US peptide-clinic settings.
Evidence it adds
Popularity / convention — not efficacy.
Basis: real-world uptake & convention — not trial data
US clinic · off-label compounding
Where / who
US functional-medicine, longevity & sports-medicine clinics — physician-prescribed via 503A/503B compounding pharmacies.
Track record
BPC-157 / TB-500: among the most commonly compounded peptides in US clinics until the Sept 2023 FDA Category 2 listing disrupted legitimate compounding — see the regulatory layer for current status.
Evidence it adds
Real-world clinical observation — physician-charted, supervised use. A genuine evidence tier, but observational: uncontrolled, unpublished, no registry, outside formal pharmacovigilance.
What it means
Off-label compounding under prescription — never an FDA-approved therapy. Removal from Category 2 is not approval.
Basis: US compounding-pharmacy practice · FDA Docket FDA-2025-N-6895
No approved clinical use
Clinical record
No country lists this exact combination as an approved therapy.
Human trials
No completed human trial of the combination. Preclinical only.
Basis required for a clinical-use tag: none found — absence shown, not hidden
Regulatory — read carefully
FDA (US)
BPC-157 / TB-500 were FDA Category 2 (compounding prohibited) 2023–Apr 2026; removed Apr 2026, under PCAC review (23–24 Jul 2026).
MHRA (UK)
Not licensed medicines. Sold as research material.
What it means
Removal from Category 2 is not approval — the compounding decision is pending.
Why it matters
No marketing authorisation = no pharmacovigilance; adverse events aren't formally tracked.
Basis: FDA Docket FDA-2025-N-6895 · PCAC 23–24 Jul 2026 — updates after the decision
Why this combination

A higher-intensity assembly run under clinic supervision. The intensity raises the case for baseline bloods and a clinician — the evidence underneath remains preclinical, with no human trial of the combination.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription. Specific timing is part of membership.
What's worth monitoring

With limited or no human safety data for this combination, there is no established marker set to monitor against — which is a reason for more caution, not less. Baseline bloods and a clinician conversation matter here. General information, not medical advice.

Combination evidence
Real-world uptake Moderate

Used in US peptide-clinic settings.

Human efficacy None

Preclinical only.

Clinical observation Observational

A decade-plus of physician-supervised, charted use — meaningful real-world signal, with no commonly-reported serious adverse-event pattern. But uncontrolled, unpublished, held in private charts (no registry) and outside formal pharmacovigilance. Not controlled evidence.

The honest ceiling

Clinic framing doesn't change the evidence — supervision is the point.

Fast facts
Compounds

BPC-157 · TB-500 · MGF · GHK-Cu

Humans exposed (est.)

Moderate — undocumented.

UK strip

GREEN — research material